ClinicalTrials.gg
CompletedNCT07646093DICLOPOPUpdated Jun 16, 2026

Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children

An interventional study of Diclofenac Potassium Medicated Lollipop in Post Operative Analgesia, Tonsillectomy and Pediatric Anesthesia, sponsored by Hospital Universitario de Caracas. Completed at 1 site in Venezuela. Open to participants aged 4 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Hospital Universitario de Caracas · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2025, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
4 Years to 12 Years
Sex
All
01

Study summary

**Brief Summary**

This study aimed to develop and conduct a preliminary clinical evaluation of a novel weight-adjusted gelatin-based diclofenac potassium medicated lollipop for the management of postoperative pain following adenotonsillectomy in children. The formulation was designed to improve analgesic adherence by providing a palatable and child-friendly dosage form suitable for oral transmucosal administration. Fifty paediatric patients aged 4 to 12 years undergoing elective adenotonsillectomy received one of three weight-adjusted diclofenac potassium lollipop doses (15 mg, 20 mg, or 30 mg) every 8 hours during the first 24 postoperative hours. The study assessed postoperative pain intensity, product acceptability, rescue analgesic use, and safety. In parallel, the formulation underwent pharmaceutical characterization, including physicochemical and microbiological quality evaluation.

Read the detailed description

This prospective single-arm pilot study evaluated a newly developed gelatin-based diclofenac potassium medicated lollipop intended for postoperative pain management after paediatric adenotonsillectomy. The pharmaceutical formulation was optimized through iterative development and characterized by physicochemical testing, content uniformity analysis, and microbiological quality assessment according to pharmacopeial standards.

Children aged 4 to 12 years undergoing elective adenotonsillectomy received weight-adjusted diclofenac potassium lollipops (15 mg, 20 mg, or 30 mg) administered every 8 hours during the first 24 postoperative hours. Pain intensity was assessed before and after each dose using age-appropriate validated pain scales. Secondary evaluations included product acceptability, requirement for rescue analgesia, and occurrence of adverse events.

The study was designed as an exploratory pilot investigation to assess the feasibility, pharmaceutical performance, preliminary clinical effectiveness, and safety of this novel paediatric drug-delivery platform, providing the basis for future randomized controlled trials and pharmacokinetic evaluation.

02

Conditions studied

  • Post Operative Analgesia
  • Tonsillectomy
  • Pediatric Anesthesia

Browse trials for

Keywords

  • diclofenac
  • medicated lollipop
  • drug delivery system
  • oral transmucosal delivery
  • pediatric formulation
  • pharmaceutical formulation
  • postoperative pain
  • tonsillectomy
  • pediatric anesthesia
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's enrollment of 50 is below the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Hospital Universitario de Caracas is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4 to 12 years.
  • Scheduled for elective adenotonsillectomy under general anaesthesia.
  • (ASA) physical status I or II.
  • Ability to tolerate oral administration of the medicated lollipop after surgery.
  • Written obtained from a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Known or to diclofenac or other non-steroidal anti-inflammatory drugs.
  • History of asthma precipitated by NSAIDs.
  • Active gastrointestinal ulcer disease or gastrointestinal bleeding.
  • Significant hepatic, renal, cardiovascular, or coagulation disorders.
  • Severe developmental delay or neurological conditions preventing reliable pain assessment.
  • Requirement for postoperative intensive care admission.
  • Refusal of participation by the patient or parent/legal guardian.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Diclofenac Potassium Medicated Lollipop

    Participants received a weight-adjusted diclofenac potassium medicated lollipop (15 mg, 20 mg, or 30 mg according to body weight) every 8 hours during the first 24 postoperative hours following adenotonsillectomy for postoperative pain management.

    Drug: Diclofenac Potassium Medicated Lollipop

Interventions

  • DrugDiclofenac Potassium Medicated Lollipop

    A weight-adjusted gelatin-based diclofenac potassium medicated lollipop formulated for paediatric postoperative analgesia. Three dosage strengths (15 mg, 20 mg, and 30 mg) were administered according to body weight every 8 hours during the first 24 postoperative hours following adenotonsillectomy.

    Also known as: DICLOPOP

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity

    Postoperative pain intensity assessed using a 10-point Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater postoperative pain intensity following administration of weight-adjusted diclofenac potassium medicated lollipops

    Time frame: 24 hours post operative

07

Study locations

1 site
  • Hospital Universitario de Caracas
    Caracas, Miranda 1040, Venezuela
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared because the study involves paediatric participants and contains potentially identifiable clinical information. Data may be made available upon reasonable request to the corresponding author, subject to institutional approval and applicable ethical and privacy regulations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07646093
Lead sponsor
Hospital Universitario de Caracas
Responsible party
Joseph Alejandro Veraza Almeida (Principal Investigator, Hospital Universitario de Caracas) — Principal investigator
First posted
Jun 12, 2026
Start date
May 1, 2025
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Jun 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion